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Abstract
Neurosecretion is critically dependent on the assembly of a macromolecular complex between the SNARE proteins syntaxin,
SNAP-25 and synaptobrevin. Evidence indicates that the binding of tomosyn to syntaxin and SNAP-25 interferes with this
assembly, thereby negatively regulating both synaptic transmission and peptide release. Tomosyn has two conserved
domains: an N-terminal encompassing multiple WD40 repeats predicted to form two b-propeller structures and a C-terminal
SNARE-binding motif. To assess the function of each domain, we performed an in vivo analysis of the N- and C- terminal
domains of C. elegans tomosyn (TOM-1) in a tom-1 mutant background. We verified that both truncated TOM-1 constructs
were transcribed at levels comparable to rescuing full-length TOM-1, were of the predicted size, and localized to synapses.
Unlike full-length TOM-1, expression of the N- or C-terminal domains alone was unable to restore inhibitory control of
synaptic transmission in tom-1 mutants. Similarly, co-expression of both domains failed to restore TOM-1 function. In
addition, neither the N- nor C-terminal domain inhibited release when expressed in a wild-type background. Based on these
results, we conclude that the ability of tomosyn to regulate neurotransmitter release in vivo depends on the physical
integrity of the protein, indicating that both N- and C-terminal domains are necessary but not sufficient for effective
inhibition of release in vivo.
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Introduction
Synaptic vesicles undergo a priming process in which they
become competent to fuse in response to a calcium signal [1].
During priming, the vesicle-associated SNARE synaptobrevin
forms a stable complex with the plasma membrane SNAREs,
SNAP-25 and syntaxin, bringing the vesicle in close apposition
with the plasma membrane [2,3,4]. Several SNARE-interacting
proteins have been shown to regulate priming, including the
syntaxin-binding partner tomosyn, which acts as a negative
regulator [5]. This conclusion is based on the inhibitory effects
of tomosyn over-expression on release in several cell types [5,6,7,8]
and on enhanced synaptic transmission in both C. elegans and
mouse mutants [9,10,11,12]. However, the molecular events by
which tomosyn mediates this inhibition remain to be fully
elucidated.
Tomosyn has two conserved domains, a large N-terminal
containing WD-40 repeats and a small C-terminal motif similar to
the SNARE-binding domain of synaptobrevin [13,14,15]. In
biochemical assays, the tomosyn SNARE domain can substitute
for synaptobrevin, forming a 4-alpha helical bundle with syntaxin
and SNAP-25, which closely resembles the crystal structure of the
fusogenic SNARE complex [5,6,16]. Based on these observations,
inhibition by tomosyn is thought to involve assembly of non-
fusogenic tomosyn SNARE complexes at the expense of fusogenic
SNARE complexes. However, while full-length tomosyn inhibits
secretion in all cell types examined, expression of the C-terminal
SNARE domain alone has produced variable results. For example,
expression of the SNARE domain in chromaffin cells had no effect
on the primed vesicle pool, and actually enhanced sustained
release [17], whereas in cultured neurons and semi-intact PC12
cells, this domain produced partial inhibition [6,12]. These data
suggest that additional tomosyn domains may contribute to its
inhibitory function. Consistent with this notion, tomosyn lacking a
SNARE motif promotes SNARE complex oligomerization in vitro
and inhibits secretion from chromaffin cells and superior cervical
ganglion (SCG) neurons [8,12,17,18]. Similarly, tomosyn with
mutations in the SNARE domain that impair syntaxin binding,
retains inhibitory function in PC12 secretion assays [19]. Brain
extracts from mouse tomosyn mutants exhibit reduced levels of
SNARE complex oligomers. Together, these observations suggest
the tomosyn N terminus contributes to the regulation of secretion,
possibly by limiting the availability of monomeric SNARE
proteins. The tomosyn N terminus has also been shown to bind
and inhibit synaptotagmin [20]. Thus, the current literature
implicates both tomosyn domains in the regulation of secretion via
several distinct molecular mechanisms. However, these roles have
only been assayed in cellulo, and their interpretation is compounded
by the presence of endogenous tomosyn. Here, we analyzed the
independent and combined functionality of tomosyn N- and C-
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in a tomosyn mutant background.
Results
The relationship between TOM-1A expression levels and
inhibitory synaptic function
C. elegans tom-1 mutants exhibit an enhanced NMJ evoked
response duration, resulting in an increased charge integral that
reflects increased priming [10]. Re-introduction of full-length
TOM-1A in cholinergic motor neurons reverses the tom-1 mutant
phenotype, producing inhibition of transmission relative to the
wild type [10,11]. This inhibitory effect was due to over-expression
of TOM-1, a consequence of the standard method used to create
transgenic lines in C. elegans, which frequently results in the
formation of a multicopy DNA array with high expression levels.
Therefore, to compare transgenic lines expressing different TOM-
1A domain constructs, we first assessed the relationship between
TOM-1A expression levels and the synaptic response at the NMJ.
TOM-1A mRNA levels were quantified by real-time PCR (qRT-
PCR), normalized to tom-1 (nu468) and plotted against evoked
charge integrals (Fig. 1). As expected, a ,6 fold increase in TOM-
1A mRNA levels greatly reduced the charge integral (72%) relative
to tom-1(nu468). A further increase in TOM-1A mRNA levels to
,11 fold produced a similar reduction of the evoked response
(80%), suggesting that the extent of inhibition was maximal within
this range of over-expression (.6 fold).
Neither TOM-1A SNARE nor DSNARE are sufficient for
TOM-1A synaptic function
To assess the ability of the SNARE and DSNARE domains to
rescue the tom-1 mutant phenotype, we created integrated
transgenic lines of either SNARE or DSNARE truncated TOM-
1A constructs in the tom-1(nu468) mutant background, expressed
under the cholinergic motor neuron promoter, Punc-17 (Fig. 2A).
By qRT-PCR, TOM-1A SNARE was expressed 23 -fold higher
than tom-1 (nu468), and TOM-1A DSNARE at ,17 fold. For full-
length TOM-1A, these mRNA levels would be expected to
produce maximal synaptic inhibition (Table 1). We then measured
cholinergic evoked responses from the NMJs of each of the
transgenic lines (Fig. 2B). Unlike full-length TOM-1A over-
expression, neither TOM-1A SNARE nor TOM-1A DSNARE
over-expression significantly reduced the evoked amplitude
relative to tom-1(nu468) (Fig. 2C). Similarly, the enhanced charge
integral and the decay kinetics of the tom-1(nu648) mutants were
not significantly rescued by over-expression of either TOM-1A
SNARE or TOM-1A DSNARE, unlike full-length TOM-1A
(Fig. 2D,E).
The linker between the tomosyn N terminus and the SNARE
domain has been postulated to act as an intramolecular switch, its
interaction with the N terminus freeing the C terminus to inhibit
SNARE complex formation [18]. To test the possibility that the
linker interaction with the TOM-1A N terminus prevents the N
terminus from inhibiting release, we examined evoked release in
tom-1(nu468) mutants expressing a truncated TOM-1A N-terminal
construct cleaved at amino acid 989, which removes both the
linker and the SNARE domain (TOM-1A(1-989). Evoked
responses from integrants expressing TOM-1A(1-989) also failed
to rescue the increased charge integral of tom-1(nu468) mutants
(charge integral of TOM-1A(1-989) 40.763.1 pC, n=4 Vs
48.266.1 pC, n=12 for tom-1(nu468), p=0.86), remaining
significantly enhanced relative to the wild type (26.562.0 pC,
n=12, p=0.017, data not shown). This result suggests that the
failure of TOM-1A DSNARE to inhibit release was not due to
interactions with the downstream linker
Both the TOM-1A SNARE and DSNARE truncated
constructs are stably expressed and localized to nerve
cord synapses
To determine whether the lack of rescue by TOM-1A SNARE
and DSNARE constructs was due to either poor expression or
mislocalization, we generated C-terminal FLAG-tagged versions of
both the SNARE and DSNARE constructs. The mRNA levels of
the FLAG-tagged constructs determined by quantitative RT-PCR
were ,26 fold for SNARE:FLAG and ,8-fold for DSNARE:-
FLAG relative to tom-1 (nu468) (Table 1). Protein extraction and
Western blotting of the transgenic worms expressing FLAG-tagged
SNARE or DSNARE constructs confirmed that proteins of the
predicted size (,7 kDa and ,110 kDa respectively) were
generated (Fig. 3A). We next examined the subcellular localization
of the truncated TOM1-A proteins in the cholinergic neurons of
C. elegans by immunostaining with anti-FLAG antibodies. Staining
was imaged along the ventral nerve cord anterior to the vulva,
where all electrophysiological recordings were performed (Fig. 3B).
The expression pattern of both SNARE:FLAG and DSNARE:
FLAG was diffusely distributed along the nerve cord in keeping
with previous observations of full-length TOM-1A tagged with
GFP [11]. Despite their normal expression pattern, both
Figure 1. Inverse-relationship between predicted full-length
TOM-1A expression levels and synaptic function. A. Represen-
tative evoked post-synaptic responses from the NMJ of tom-1(nu468),
wild type and two TOM-1A integrated lines, SY1229 and SY1242,
expressed in the tom-1(nu468) mutant background respectively. B.
Average charge integral for evoked responses of tom-1(nu468) (n=20),
wild type (n=73) and tom-1(nu468) over-expressing TOM-1A integrated
lines SY1242 (,6 fold mRNA levels) (n=7) and SY1229 (,12 fold mRNA
levels) (n=7) plotted against predicted TOM-1A expression levels based
on quantitative real-time RT-PCR (qRT-PCR) normalized to C. elegans
actin (act-1) transcript levels. Data plotted as mean 6 SEM (significance
values relative to tom-1(nu468), *** p#0.0001, Mann Whitney T-test).
Representative evoked NMJ traces are displayed above each strain.
doi:10.1371/journal.pone.0026185.g001
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1(nu468) phenotype, recapitulating the results observed in the
untagged lines (Fig. 4). These data indicate that the inability of
either the TOM1-A SNARE or DSNARE domain to restore
TOM-1 function was not due to misexpression.
Over-expression of TOM-1A SNARE or DSNARE fails to
inhibit synaptic release in wild-type worms
In cultured neurons, in which endogenous tomosyn is present,
expression of either tomosyn SNARE or tomosyn DSNARE has
been reported to inhibit synaptic transmission [12,18]. To address
whether C. elegans TOM-1A SNARE or DSNARE expression has
an inhibitory effect in the presence of endogenous TOM-1, we
crossed the truncated lines into the wild-type background. Evoked
synaptic responses were not inhibited by either TOM-1A SNARE
or DSNARE, whereas full-length TOM-1A over-expression
caused a significant decrease in evoked charge integral (Fig. 5).
Co-expression of SNARE and DSNARE constructs fails to
reconstitute TOM-1A function
To address whether co-expression of the TOM-1A SNARE and
TOM-1A DSNARE constructs could reconstitute TOM-1A
function, we co-expressed both constructs (SNARE/DSNARE)
in the tom-1(nu468) background. Unlike full-length TOM-1A, co-
expression of TOM-1A SNARE/DSNARE failed to rescue the
enhanced evoked response of the tom-1(nu468) mutant (Fig. 6A–C).
Similarly, co-expression of TOM-1A SNARE/DSNARE failed to
recapitulate the inhibitory effect of full-length TOM-1A over-
expression in the wild-type background (Fig. 6 D–F).
Discussion
Although the inhibitory role of tomosyn in exocytosis is well
established, the molecular events underlying this negative
regulation remain to be fully elucidated [21]. To further our
understanding of tomosyn function, we examined the inhibitory
capacity of the two conserved tomosyn domains in vivo. Our results
indicate that the integrity of C. elegans TOM-1 is critical for its
inhibitory function, as neither TOM-1A SNARE nor DSNARE
were able to restore TOM-1 function, when expressed separately
or together in tom-1 mutants.
Although biochemical evidence strongly implicates the tomosyn
SNARE domain in the regulation of SNARE complex formation
[6,12,16], the inhibitory capacity of this domain depends on the
experimental context [6,17,18]. Whereas the tomosyn SNARE
domain expressed in cultured SCG neurons [12] or applied to
inverted PC12 cell plasma membrane sheets [6] inhibits secretion,
evoked release is unaffected in both chromaffin cells [17] and, as
shown here, in C. elegans motor neurons. What experimental
variable might account for these different outcomes? Since
tomosyn SNARE-dependent synaptic inhibition in SGC cells has
only been assayed in wild-type neurons, it is possible that the
SNARE domain may inhibit release by altering intramolecular or
intermolecular interactions of endogenous tomosyn. However, the
inability of the tomosyn SNARE domain to inhibit release when
endogenous tomosyn was present in wild type C. elegans as well as
chromaffin cells argues against this possibility. Alternatively, the
ability of the SNARE domain to impact SCG neuron and PC12
ghost cell secretion may reflect the achievement of higher
expression levels by microinjection or direct application in these
cells. While we cannot rule out this explanation, the lack of an
inhibitory effect of SNARE over-expression in either chromaffin
cells or C. elegans neurons, at levels effective for full-length tomosyn,
argues against the physiological relevance of the observed
Figure 2. SNARE and DSNARE domains of TOM-1A fail to rescue
tom-1(nu468) mutants. A. Schematic showing full-length TOM-1A
(SY1242) and the SNARE (SY1230) and DSNARE (SY1231) truncated
constructs used to generate the integrated transgenics. The position of
the early stop at amino acid W212 for tom-1(nu468) is indicated by the
arrow B. Representative traces of evoked post-synaptic responses and
plots of evoked amplitude (***, p=0.006) (C), evoked charge integral
(**,p=0.0014, ***, p=0.007) (D) and evoked half-time decay
((**,p=0.001, ***, p,0.0001) (E). All data are expressed as mean 6
SEM. The Mann Whitney T-test was used to determine significance
values relative to tom-1(nu468). The sample size (n) is indicated as a
number in each bar.
doi:10.1371/journal.pone.0026185.g002
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molecular events underlying the inhibitory capacity of the tomosyn
SNARE domain are differentially tuned in the neurons of
vertebrates and C. elegans. The vertebrate tomosyn SNARE
domain has been shown to readily form tomosyn SNARE
complexes in cell free assays and to compete with synaptobrevin
in the assembly of SNARE complexes [6,16]. We know from in
vitro assays that the C. elegans TOM-1 SNARE domain is much less
efficient than the SNARE domain of C. elegans synaptobrevin
(SNB-1) in promoting the assembly of recombinant SNARE
complexes [10]. Moreover, the C. elegans SNAP-25 homolog (RIC-
4) is much less efficient than vertebrate SNAP-25 in facilitating
both TOM-1 and SNB-1-containing SNARE complex formation
in vitro. Substituting vertebrate SNAP-25 for RIC-4 greatly
enhances levels of both C. elegans TOM-1 and SNB-1 containing
SNARE complexes in vitro [10]. Thus, we postulate that in vivo, C.
elegans TOM-1 SNARE may be much less effective in inhibiting
fusogenic SNARE complex formation relative to the vertebrate
tomosyn SNARE domain in SCG cells. For this explanation to fit
the current data, it would suggest that there must also be
differences in the ability of the vertebrate tomosyn SNARE
domain to impact dense core granule secretion in chromaffin cells
relative to SCG synapses.
In contrast to the SNARE domain, expression of the tomosyn
N-terminal domain inhibits release from both chromaffin [17] and
SCG cells [12,18,20], as does full-length tomosyn lacking SNARE-
syntaxin interactions in PC12 cells [19]. Yet, TOM-1 lacking the
SNARE domain fails to rescue the C. elegans tom-1 mutant
phenotype. A recent analysis of rat tomosyn mutants indicates that
tomosyn promotes the formation of SNARE complex oligomers,
providing a possible second mechanism by which tomosyn may
Table 1. DDCt-values for TOM-1A transgenic lines.
Strain Transgenic Line DDC(t)-values for TOM-1A primers DDC(t)-values for SNARE primers
SY1230 tom-1;p 17:SNARE 0.72 22.6
SY1232 tom-1;p17:SNARE-FLAG 0.58 98
SY1231 tom-1;p 17:DSNARE 16.56 1.89
SY1233 tom-1;p 17:DSNARE-FLAG 14.52 0.59
SY1242 tom-1;p 17:TOM-1A 5.03 7.31
SY1229 tom-1;p 17:TOM-1A 14.03 10.85
Transgene mRNA levels were determined by qRT-PCR using primers specific for TOM-1A N-terminal (starting at bp1840) and the SNARE domain in the tom-1(nu468)
mutant background. DDC(t) values were normalized to tom-1(nu468) using act-1 transcript levels as a calibrator.
doi:10.1371/journal.pone.0026185.t001
Figure 3. Both TOM1-A SNARE and DSNARE are stably
expressed and localized at synapses. A. The FLAG tagged SNARE
and DSNARE constructs are of the predicted size on Westerns. B.
Representative confocal images of SNARE::FLAG and DSNARE::FLAG
expression in the ventral nerve cord (VNC) anterior to the vulva, the
region used for electrophysiological recording. Staining in the lateral
nerve cord (LNC) was also observed. Scale bar is 50 mm.
doi:10.1371/journal.pone.0026185.g003
Figure 4. Flag-tagged TOM-1A SNARE and DSNARE transgenics
phenocopy untagged lines. A. Representative evoked response
traces for SNARE::FLAG (SY1232) and DSNARE::FLAG (SY1233) express-
ing lines. B. Plots of average evoked amplitude and (C) evoked charge
integral. All data are expressed as mean 6 SEM, the sample size (n) is
indicated as a number in each bar. Mann Whitney T-tests showed values
were not significantly different.
doi:10.1371/journal.pone.0026185.g004
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sequestration of SNARE proteins [12]. Although the precise
mechanism underlying SNARE complex oligomerization is
unknown, the tomosyn N-terminal domain recapitulates this effect
in cell free assays [12]. Since the isolation of native SNARE
complexes from C. elegans has yet to be achieved, we are unable to
address whether tom-1 mutants show a similar reduction in
SNARE complex oligomerization. Regardless, the inability of
TOM-1A DSNARE over-expression to rescue tom-1 mutants or
inhibit release in wild type C. elegans suggests that, in this in vivo
context, expression of full-length TOM-1 is required for
functionality.
How might linkage of the two TOM-1 domains within the full-
length protein contribute to the ability of TOM-1 to negatively
regulate synaptic transmission? Recently, evidence for a third
tomosyn inhibitory mechanism has emerged, which involves a
calcium-dependent interaction between the rat tomosyn N
terminus and the vesicle-associated calcium-sensor, synaptotagmin
[20]. The binding of tomosyn to synaptotagmin interferes with the
in vitro membrane-bending ability of synaptotagmin, a function
implicated in the vesicle fusion process [22,23]. Furthermore,
injection of the synaptotagmin cytoplasmic domain represses the
ability of the tomosyn N-terminal domain to inhibit release from
cultured SCG neurons, suggesting the interaction between the
tomosyn N-terminal domain and endogenous synaptotagmin
underlies this inhibitory effect. Interestingly, synaptotagmin
binding to full-length tomosyn also enhances the ability of the
tomosyn SNARE domain to form tomosyn SNARE complexes
[20]. These data imply that the tomosyn N-terminal interaction
with synaptotagmin may favorably position the C-terminal
tomosyn SNARE domain to initiate tomosyn SNARE complex
assembly. This result suggests that the integrity of tomosyn could
facilitate simultaneous interference with synaptotagmin function
and SNARE complex assembly, via the linked N- and C-terminal
domains, respectively. In this model, the spatial proximity of the
two tomosyn domains, would be an important requirement for the
dual inhibition and may explain why the integrity of TOM-1 is
essential for inhibitory function at C. elegans synapses.
In conclusion, we have conducted the first in vivo analysis of
TOM-1 structure-function in a tom-1 mutant background. Based
on our results we conclude that the physical link between the N-
and C-terminal domains is critically important for the normal
function of TOM-1. This result differs from previous studies in
cultured mammalian cells, in which over-expression of the
SNARE domain produced variable results and the N terminus
inhibited secretion. It remains to be seen whether expression of
either the tomosyn SNARE or delta-SNARE domains in the
recently available mouse tomosyn mutants restores tomosyn
function in vivo [18].
Materials and Methods
Genetics
Nematode strains were maintained at 20–25uC on standard
NGM media plates seeded with OP50 bacteria. The wild type
used was Bristol N2 and the tom-1 mutant KP3293, tom-1(nu468).
TOM-1 constructs were SY1229, tom-1(nu468);jaIs1078[Punc17:
tom-1A(+);Pmyo-2:GFP]; SY1242, tom-1(nu468);jaIs1052[Punc17:tom-
1A(+);Pmyo-2:GFP]; SY1230, tom-1(nu468);jaIs1079[Punc17:tom-1A
SNARE;Pttx:RFP]; SY1231, tom-1(nu468); jaIs1080[Punc17:tom-1A
DSNARE;Pttx:RFP]; SY1513, tom-1(nu468);jaI1098[Punc17;tom-1A
TOM1A(1-989);Pttx:RFP]; SY1232, tom-1(nu468);jaIs1081[Punc17:
tom-1A SNARE:FLAG;pmyo-3:GFP]; SY1233, tom-1(nu468);jaIs1082
[Punc17: tom-1A DSNARE:FLAG;pttx-3:GFP]; SY1234, N2;jaIs1079;
SY1235, N2;jaIs1080; SY1237, N2;jaIs1052; SY1239, tom-
1(nu468);jaIs1079;jaIs1080; SY1240, N2;jaIs1079;jaIs1080.
Crosses were performed using standard genetics techniques, and
the presence of the tom-1(nu468) mutation was confirmed by
sequencing.
Tomosyn constructs and transgenes
1) Full-length tom-1A. Full-length tom-1A cDNA was
amplified from jaIs1052 strain [10] using the primers
GTAGCATGCGCTGGGGTATTGCAAAAAGAG and GTC-
GCATGCCTAGAAGTTGTACCACTTC and TOPO-cloned,
creating pAB29. pUNC-17::TOM-1A from pAB29 was cloned
into pAB30 using SphI restriction sites and the resulting plasmid
was named pAB32.
2) TOM-1A SNARE. The tom-1A SNARE domain (aa 1059–
1124) was amplified from pAB29 using primers GCGGA-
Figure 5. Over-expression of TOM1-A SNARE or DSNARE
constructs do not inhibit synaptic release in the wild-type
background. A. Representative evoked traces for full-length TOM-1A
(SY1237), SNARE (SY1234) and DSNARE (SY1235) expressing transgenes
in the wild-type background. (B) Average evoked amplitude and (C)
Average charge integral were only significantly reduced by full-length
TOM-1A relative to wild type (***, p=0.0005, and p=0.0007 for B and C,
respectively). All data are expressed as mean 6 SEM, the sample size (n)
is indicated as a number in each bar, significance values obtained with
the Mann Whitney T-test.
doi:10.1371/journal.pone.0026185.g005
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ACTAGAAGTTGTACCACTTC and TOPO-cloned, creating
pAB37. The tom-1A SNARE domain was then subcloned into
pAB36 containing pUNC-17 using BamHI/MscI restriction sites,
creating pAB40.
3) TOM-1A DSNARE. The tom-1A DSNARE domain (aa 1–
1045 ) includes the WD40 repeats and the downstream 57 amino
acid linker, based on conserved sequence alignments [24]
amplified from pAB29 using primers AGAGTCATCCCTCAG-
AACAG and GTCTAGGATCCATGCATCGGATTCACTC-
CAGAACTATTC, TOPO-cloned creating pAB47. tom-1A
DSNARE was subcloned into pAB36 containing pUNC-17 using
BamH restriction sites, creating pAB48.
4) TOM-1A (1-989) lacking the linker and SNARE
domain. TOM-1A(1-989) was amplified from pAB29 using
primers AGAGTCATCCCTCAGAACAG and TATGCGGCC-
GCTGACTCGCCTGTTTGCTCGGCAATTTC and topo-
cloned, creating pAB46. The tom-1A Dlinker was subcloned into
pAB36 containing pUNC17 using BamHI/NotI restriction sites,
creating pAB49.
5) TOM-1A SNARE:FLAG. The NsiI restriction site
(underlined) was introduced by site-directed mutagenesis using
primers GTGGTACAACTTCATGCATTAGTGGCCAAAG-
GAC and GTCCTTTGGCCACTAATGCATGAAGTTGT-
ACCAC using pAB40 as a template, creating pAB43. The
FLAG oligos with NsiI sticky ends and 59-phosphorylated were
made as separate oligonucleotides, PTGATTACAAGGATG-
ACGACGATAAGCTTATGCA and TAAGCTTATCGTCGT-
CATCCTTGTAATCATGCA, annealed and ligated into the
NsiI site of pAB43, creating pAB50.
6) TOM-1A DSNARE:FLAG. The NsiI restriction site was
included in the primer GTCTAGGATCCATGCATCGGAT-
TCACTCCAGAACTATTC to bypass the site-directed mutage-
nesis step. Annealed FLAG oligonucleotides were ligated into
pAB48 NsiI restriction site, creating pAB58.
Real-time PCR
Quantitative real-time PCR was performed as described
previously [10]. Briefly, C. elegans total RNA was isolated using a
Trizol reagent as described by the manufacturer (Invitrogen,
Carlsbad, California, United States). mRNA was reverse tran-
scribed using the SuperScript III First Strand Synthesis Kit with
oligo-dT primers (Invitrogen Carlsbad, California, United States).
Real-time PCR was preformed using the following target specific
primers: for tom-1A N-terminal (Forward-TCATCGTACGG-
TATCATTGC and Reverse- AGCTTCCAGACTGATTG-
Figure 6. Co-expression of SNARE and DSNARE constructs failed to reconstitute TOM-1A function. A. Representative evoked response
traces for tom-1(nu468), and with full-length TOM-1A over-expression (SY1242) or co-expression of SNARE and DSNARE (SY1239), (B) average evoked
amplitudes (***, p=0.0006) and (C) average evoked charge integrals (**, p=0.0021). (D) Representative evoked response traces for wild type alone,
and with TOM-1A over-expression (SY1237) or co-expression of SNARE and DSNARE (SY1240), (E) average evoked amplitudes (**, p=0.0033) and (F)
evoked charge integrals (**, p=0.0037). All data are expressed as mean 6 SEM, the sample size (n) is indicated as a number in each bar, significance
values obtained with the Mann Whitney T-test.
doi:10.1371/journal.pone.0026185.g006
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GCCATGGCTTTACAGAACTT and Reverse- TCTCGAG-
GATAAACTCATTGC) which targeted exon22/23, and for act-
1 (Forward-GCTGGACGTGATCTTACTGATTACC and Re-
verse-GTAGCAGAGCTTCTCCTTGATGTC). SYBR green
(Biorad) was used for amplicon detection and quantitation using
the MJ Research Opticon2 real-time thermocycler (Bio-Rad,
Hercules, California, United States). Relative mRNA levels were
quantified using the method detailed by [25]. Actin was used as a
reference for calibration [26]. The levels for both tom-1 and the
SNARE domain are reported as the fold difference relative to the
calibrator, tom-1 (nu468).
Biochemistry
1) Liquid Culture. L1 stage worms were harvested from 6
freshly-starved 100 mm agarose plates and added, along with
concentrated HB101 bacteria, to 500 ml S medium supplemented
with 5 ml 10,000 U/ml penicillin (Cellgro), 10 mg/ml
streptomycin (Cellgro) and 10,000 U/ml nystatin (Sigma) in a
2.8 L fernbach flask. After 3 days of growth at 20uC, adult worms
were harvested through a 35 mM nitex filter. Worms left in the
filter were washed once with M9, 1X lysis buffer (50 mM HEPES
pH 7.4, 1 mM EGTA, 1 mM MgCl2, 100 mM KCl, 10%
glycerol, 0.05% NP-40) and 1X lysis buffer containing a
complete Mini, EDTA-free protease inhibitor cocktail tablet
(Roche; 1 tablet/12 mls). Worms were spun down at 800 g for
2 minutes between washes. A 1:1 mix of worms:lysis buffer was
slowly pipetted into liquid nitrogen then ground to a fine powder
in a mortal and pestle.
2) Extract Preparation. Thawed ground worm powder was
sonicated using a Branson sonication tip for 3 minutes (15 seconds
on, 45 seconds off) at 30% amplitude and for 30 seconds at 40%
amplitude. Samples were cooled in an ice bath for 2 minutes in
between each minute of sonication. Sonicated samples were
centrifuged in a Sorvall Ultra80 centrifuge, using a TH-641 rotor,
for 11.5K RPM for 10 minutes, and then the supernatant was
centrifuged at 29K RPM for 20 minutes. The supernatant was
frozen in liquid nitrogen in 1 ml aliquots and stored at 280uC.
3) Immunoprecipitation. 100 ml of FLAG antibody-
conjugated agarose beads (Sigma F2426) were washed twice
with 1 ml PBST, once with 1 ml PBS, twice with 1 ml 0.1 M
glycine and twice with 1 ml ice cold lysis buffer with 0.1 mM
DTT. Beads were centrifuged at 4uC at 4K RPM for 2 minutes
between washes. Beads were rotated for 2 hours at 4uC with 1 ml
of clarified extract. Beads were briefly rinsed twice then washed
three times, by rotating for 5 minutes at 4uC, with 1 ml 0.1 mM
DTT lysis buffer. Beads were incubated with 9 ml of 600 mg/ml
FLAG peptide at 4uC for 1 hour in Protein LoBind tubes
(Epindorf). Supernatant was transferred to fresh tubes and mixed
with equal volume 2X Laemmli SB and stored at 220uC.
4) Western blotting. Samples were analyzed by 12% SDS-
PAGE (0.1% SDS). The nitrocellulose membrane was blocked at
RT in 5% milk/TBST for 1 hour then incubated with HRP-
conjugated 1u anti-FLAG antibody (Sigma A8592) at a 1:500
dilution in TBST overnight at 4uC. Membrane was washed four
times for 10 minutes with TBST shaking at RT then incubated
with 2 ml HRP substrate (Amersham) for 5 minutes prior to
exposure to film.
Immunohistochemistry
Immunohistochemistry was performed on dissected split-open
worms, as previously described [27] after fixation with 4%
paraformaldehyde in PBS for 30 minutes. Preps were then washed
36with TBST for 10 minutes, before blocking with 5% BSA for
1 hour. Mouse antibodies against FLAG (Sigma) were used at a
final dilution of 1:100 in PBS and 0.5% Triton X-100 with 5%
BSA overnight. Anti-mouse tetramethylrhodamine isothiocyanate-
conjugated secondary antibody (Jackson ImmunoResearch, West
Grove, PA) was used at a 1:500 dilution for 1 hour. Images were
obtained with a 606 objective on an Olympus Optical FV- 500
laser-scanning confocal microscope.
Electrophysiology
Electrophysiological methods were as previously described [27]
with the following modifications: Ventral body wall muscle cells
were recorded in the whole-cell voltage-clamp mode (holding
potential 260 mV) using an EPC-10 patch-clamp amplifier and
digitized at 1 kHz. The extracellular solution consisted of (in mM):
NaCl 150; KCl 5; CaCl2 5; MgCl2 4, glucose 10; sucrose 5;
HEPES 15 (pH 7.4, ,340mOsm). The patch pipette was filled
with (in mM): KCl 120; KOH 20; MgCl2 4; (N-tris[Hydrox-
ymethyl] methyl-2-aminoethane-sulfonic acid) 5; CaCl2 0.25;
Na
2ATP 4; sucrose 36; EGTA 5 (pH 7.2, ,315mOsm). Evoked
responses were stimulated with a 2 ms depolarizing pulse delivered
via a pipette placed on the anterior ventral nerve cord. Data were
acquired using Pulse software (HEKA, Southboro, Massachusetts,
US) and subsequently analyzed and graphed using Pulsefit
(HEKA), Mini Analysis (Synaptosoft Inc., Decatur, Georgia, US)
and Igor Pro (Wavemetrics, Lake Oswego, Oregon, US).
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